Abstract: The invention provides compounds including a CpG oligodeoxynucleotide sequence linked to a lipid by a linker and related compositions and methods. The invention features a compound consisting of the nucleotide sequence of SEQ ID NO:1, at its 5? end, bonded or linked by a linker to a lipid. Further, the invention features a method of treating a cancer in a human patient, comprising administering to the patient the compound. Further, the invention features a pharmaceutical composition including the compound and a pharmaceutically acceptable carrier. The invention features a kit including (I) the compound or a composition comprising the compound; and (ii) a protein comprising SEQ ID NO:2 or SEQ ID NO:3.

Abstract: The present disclosure provides nucleic acid constructs for the treatment of cancer, comprising a cancer-specific promoter and one or more therapeutic genes.

Abstract: A mannose derivative is an isonitrile-containing mannose derivative of formula (I), including different linking groups X: A radioactive preparation is provided, including a radiolabeled compound formed by radiolabeling the mannose derivative with a radionuclide. An application of the radioactive preparation in the diagnosis and treatment of tumors is also provided.

Abstract: The invention provides a chromogenic ?-lactam molecule that retains its diagnostic color change response when modified for conjugation to another molecule.

Abstract: Systems and methods are disclosed for quantifying blood flow using time-varying kinetic modeling of high temporal-resolution dynamic positron emission tomography (PET) data. A single tracer is introduced into the body. A first set of images is acquired, via PET, of at least a portion of the body at a plurality of predetermined time intervals. Based on the first set of images, an intensity of the tracer in the at least the portion of the body is determined as a function of time. The intensity of the tracer as a function of time is modeled using a time-varying kinetic model. Based on the model, the blood flow through the at least the portion of the body is quantified. Additional images may be acquired and used to quantify additional parameter(s), such as glucose metabolism, amyloid load, etc., with the single tracer.

Abstract: The present invention relates to a sulfonated polystyrene derivative of formula I for use in the treatment and/or prophylaxis of cat flu, especially infection caused by feline calicivirus or feline herpesvirus, alone or in combination therapy.

Abstract: In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.

Abstract: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target.

Abstract: Compositions and methods for treating, detecting, and diagnosing cancer are disclosed.

Abstract: Improved RNA interference (RNAi) efficiency in insects is disclosed herein. In particular, certain embodiments of the presently-disclosed subject matter relate to use of nanoformulations of double-stranded RNA (dsRNA) to limit nuclease degradation of the dsRNA, and enhance cellular update and intracellular transport to improve delivery of the dsRNA to enhance RNAi in insects.

Abstract: The disclosure relates to antigen detection reagents and related methods, systems, and kits. The reagents comprise an antigen-binding molecule conjugated to an inorganic component. In some embodiments, the inorganic component possesses catalytic functionality to provide a detectable signal. In some embodiments, the catalytic inorganic component is or comprises a bimetallic nanoparticle. In other embodiments, the inorganic component is a nanoflowers that provides a physical scaffold onto which the antigen-binding component and a reporter component can be loaded, resulting in augmented antigen-binding and reporting capabilities.

Abstract: An inhaling device for heavy metal salts and a method of use thereof for medical treatment is provided. The device has a housing defining an interior volume. A mouthpiece is disposed at a terminal end of the housing. A slot is also disposed in the housing, wherein the slot is configured to receive a removably securable cartridge. The cartridge includes at least one heavy metal salt in a solution. Upon securement of the cartridge into the housing, the mouthpiece is in fluid communication with the solution. A battery powered heating element is disposed in the interior volume of the housing, wherein the heating element is in thermal communication with the cartridge when the cartridge is secured within the housing. In use, a user can heat the solution via the heating element and inhale the solution via the mouthpiece.

Abstract: Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19F molecular species and to generate probes with distinct 19F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18F isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

Abstract: An immunomagnetic nanocapsule includes a core, a shell and an outer layer. The shell is formed by a complex, and the complex is fabricated by a combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles via a hydrophobic interaction. The core is encapsulated in the shell. The outer layer includes at least one antibody immobilized to outside of the shell to form the outer layer, wherein the antibody is an immune checkpoint inhibitor and/or a T cell expansion antibody.

Abstract: A method of diagnosing a mitochondrial related disease in a subject includes administering a deuterated metabolic water precursor to the subject, measuring a rate of deuterated water formation in a sample region of the subject, and comparing the measured deuterated water formation in the sample region to a control value. A difference between the rate of deuterated water formation in the sample region compared to a control value is indicative of a mitochondrial related disease.

Abstract: The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals.

Abstract: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic duster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18F isotope F is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

Abstract: A method and system for predicting the onset of a disease is provided.

Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.

Abstract: Method for generating contrast agent concentration map from a non-contrast enhanced Computed Tomography scan, a contrast enhanced Computed Tomography scan and corresponding spectral Computed Tomography data, comprising: a. Generating at least two different primary contrast agent concentration maps out of the non-contrast enhanced Computed Tomography scan, the contrast enhanced Computed Tomography scan and the spectral Computed Tomography data, b. Performing a local quality analysis of each primary contrast agent concentration map c. Determining local volumetric weights for each primary contrast agent concentration map based on the local quality analysis, and d. Generating a secondary contrast agent concentration map based on the two primary contrast agent concentration maps and on their corresponding local volumetric weights.

Abstract: A method to determine presence of a disease condition in a medical patient by evaluating conductivity information. Point-attributes values obtained from highly accurate conductivity data-sets taken as a function of time, over a period of time, are compared to previously determined threshold values. Z-scores may be determined to combine a plurality of point-attribute values in formulation of a composite score for a patient. Sometimes, z-scores are weighted by overall accuracy of the point-attribute in predicting presence of the disease.

Abstract: There are disclosed compositions and methods to render nucleic acids resistant to nuclease digestion while maintaining sequence selective hybridization competency. The approach relies on utilizing nucleic acids as the polar head group of a nucleic acid-polymer amphiphile in order to assemble well-defined, discrete micellar nanoparticles. Dense packing of nucleic acid in the micelle corona allows for hybridization of complementary oligonucleotides while prohibiting enzymatic degradation.

Abstract: An object of the present invention is to provide a method for accurately evaluating the specific incorporation of D-glucose into cells. The present invention as a means for achieving the object is characterized by comprising contacting a D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells and an L-glucose derivative that has a fluorescent chromophore in the molecule with different cells in the same cell strain to be evaluated, respectively, comparing the fluorescence emitted by the D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells with the fluorescence emitted by the L-glucose derivative that has a fluorescent chromophore in the molecule, and evaluating the specific incorporation of D-glucose into cells relative to L-glucose by taking the difference between the two kinds of fluorescence intensities.

Abstract: The present invention provides methods and compositions useful for supplying high throughput nucleic acid sequencing systems with templates. The methods circumvent the need for costly, labor-intensive cloning and cell culture methods and can be scaled to accommodate template production for a variety of sequencing applications, e.g., sequencing individuals' genomes, sequencing subpopulations of transcripts from a gene of interest, and/or gene expression profiling. Particularly preferred embodiments of the methods vastly improve the preparation of cDNA from mRNA samples, e.g., by randomizing errors introduced during the process, thereby allowing these errors to be readily distinguished from true variants present in the mRNA samples.

Abstract: Aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells are described. The aptamers can be identified by screening a large pool of randomly generated aptamers to obtain a discrete set of aptamers that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma. The aptamers can also be linked or complexed with anticancer agents or imaging agents for use in therapy or diagnosis.

Abstract: The invention provides a conjugate of a biologically active molecule and a 5-fluoro-5-deoxypentose or a 3-fluoro-3-deoxypentose, wherein the biologically active molecule is selected from the group consisting of proteins, peptides, nucleic acids, oligosaccharides and polysaccharides.

Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.

Abstract: Provided are adenosine analog compounds such as that act as P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.

Abstract: The invention disclosed herein discloses selected ribose isomers that are useful as PET probes (e.g. [18F]-2-fluoro-2-deoxy-arabinose). These PET probes are useful, for example, in methods designed to monitor physiological processes including ribose metabolism and/or to selectively observe certain tissue/organs in vivo. The invention disclosed herein further provides methods for making and using such probes.

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment.

Abstract: Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2?, 4?, and 11?,as well as uses for the compounds for imaging, and the like.

Abstract: Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2?, 4?, and 11?, as well as uses for the compounds for imaging, and the like.

Abstract: Methods for treating renal cancer by administration of certain 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide compounds, especially 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide (Orellanine), conjugated to an alpha-emitting radionuclide (e.g. Astatine-211) to increase the efficacy of the formulation and/or a large molecule (e.g. a oligomer/polymer such as a PEG or a polysaccharide such as a dextran or a Ficoll®) to reduce the filtration and consequently the renal exposure. Particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods can be used.

Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.

Abstract: Tooth stain resulting from exposure to coloring agents contained in food and beverages, generally termed foodstuffs, is reduced, prevented and/or reversed by the addition of consumable anti-staining materials to the foodstuff anytime prior to ingestion. The anti-staining materials may be introduced into the foodstuff during the manufacturing process or added by the consumer at the time of preparation or use. A number of materials which interact with tooth stains and/or staining agents to counteract their effect and/or reduce their coloration as well as substances which interact with teeth to block the interaction of staining agents with teeth are disclosed.

Abstract: Provided in the following specification are precursors or synthons that are useful for the synthesis of various arabinose based chemical and radiochemical derivatives of nitroimidazole-containing azomycin arabinosides, such as radioiodinated 1-#-D-(5-deoxy-5-[I*]-iodoarabinofuranosyl)-2-nitroimidazole (*IAZA), and radiofluorinated 1-#-D-(5-deoxy-5-[18F]-iodoarabinofuranosyl)-2-nitroimidazole (18FAZA). Such compounds are useful in imaging, therapy, or radiotherapy. Further, various syntheses of said precursors/synthons and the incorporation of said precursors/synthons into kits is provided. The precursors/synthons provided herein allow for an improved and facile manufacturing process for nitroimidazole-containing azomycin arabinosides.

Abstract: A method for attaching an implant to tissue is disclosed. In embodiments, a method includes applying a sprayable material to tissue, the sprayable material possessing functional groups capable of binding to tissue. The sprayable material also possesses functional groups capable of binding to an implant. In embodiments, the functional groups capable of binding to an implant include nucleotides. In such a case, the implant possesses complementary nucleotides capable of binding to the nucleotides on the sprayable material, thereby permitting hydrogen binding between the two. The implant may thus be affixed to tissue, and repositioned as necessary, prior to more permanent attachment utilizing means such as sutures, tacks, etc.

Abstract: The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals.

Abstract: The invention described herein relates to the composition of a liquid in which a silver ion moiety can act as a preservative as well as an astringent for the inhibition of microbial infections of the eye.

Abstract: Methods of treating malnutrition are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.

Abstract: Magnetic beads that include polyvalent ligands comprising various carbohydrates are described. Methods for fabricating such magnetic beads are also provided as well as methods of their use to capture and enrich pathogen cell population for subsequent culture, lysis and identification.

Abstract: Methods of treating malnutrition are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.

Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.

Abstract: A method of diagnosing a CD206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to CD206. A method of treating a CD206 expressing cell-related disorder is also provided, as well as an ex vivo method and kit for quantitating the number of cells expressing CD206 in a bodily fluid.

Abstract: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.

Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.

Abstract: Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models of diseases or disorders.

Abstract: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and v) eluting the 223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.